The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. V. Alternative method for preparation of serum albumin-methotrexate derivative
- PMID: 2370913
The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. V. Alternative method for preparation of serum albumin-methotrexate derivative
Abstract
An alternative method for the preparation of human serum albumin-methotrexate derivative (HSA-MTX) using N-hydroxysuccinimide ester of methotrexate (MTX) was compared with that using the water-soluble carbodiimide (WSC) assistance. The prepared derivative was tested to find the advantages and drawbacks of this method. The N-hydroxysuccinimide ester method is more laborious than that using WSC but some reasons speak in favor of this method. The formation of protein-protein conjugates during the reaction was negligible and under specific conditions more MTX molecules could be bound to protein than by the WSC method. However, some disadvantages of this method were found: A laborious preparation, a small degree of denaturation of protein during the synthesis and, moreover, the binding of MTX to protein did not always take place through NH2-groups of protein but through some other groups (--OH, --SH) as well. These couplings were not so stable as an amidic (or peptidic) bond. In water environment they were hydrolyzed and MTX was slowly released. If there is no difference in a small fraction of protein-protein conjugates, the WSC-assisted method possesses evident advantages over the active MTX ester one, mainly because of the simple preparation of the stable derivative.
Similar articles
-
The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. III. Human serum albumin-methotrexate derivative, its preparation and basic testing.Neoplasma. 1988;35(3):329-42. Neoplasma. 1988. PMID: 3405341
-
The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. IV. Therapy of murine melanoma B16 by human serum albumin-methotrexate derivative.Neoplasma. 1988;35(3):343-9. Neoplasma. 1988. PMID: 3405342
-
Nature of linkage and mode of action of methotrexate conjugated with antitumor antibodies: implications for future preparation of conjugates.Cancer Res. 1988 Jun 15;48(12):3330-5. Cancer Res. 1988. PMID: 3259466
-
The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. II. Chemotherapy of Gardner lymphosarcoma with pea seed lectin-methotrexate derivative.Neoplasma. 1986;33(4):409-16. Neoplasma. 1986. PMID: 3762803
-
The chemistry of methotrexate and its analogues.Med Res Rev. 1988 Jan-Mar;8(1):95-155. doi: 10.1002/med.2610080106. Med Res Rev. 1988. PMID: 3278183 Review. No abstract available.
Cited by
-
Serum albumin (SA) accumulation by bronchogenic tumours: a tracer technique may help with patient selection for SA-delivered chemotherapy.Eur J Nucl Med. 1995 Sep;22(9):989-96. doi: 10.1007/BF00808409. Eur J Nucl Med. 1995. PMID: 7588953
-
Characterization and in vitro methotrexate release from methotrexate/gelatin conjugates of opposite conjugate bond polarity.Pharm Res. 2000 Oct;17(10):1309-15. doi: 10.1023/a:1026460023503. Pharm Res. 2000. PMID: 11145239
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources